5Y Capital

GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Geneoscopy, LLC is a diagnostic company based in Saint Louis, Missouri, focused on developing non-invasive solutions for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, Geneoscopy utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel aimed at identifying colorectal cancer by detecting the effects of cancer-related DNA mutations. The company is committed to improving colorectal cancer screening compliance and facilitating early detection, thereby reducing the associated morbidity and mortality. By employing a novel methodology to extract human RNA transcripts from stool samples, Geneoscopy aims to provide a reliable alternative to traditional colonoscopies, which are often viewed as unpleasant and invasive. In addition to its colorectal cancer diagnostic test, Geneoscopy is also exploring other potential applications of its RNA technology for additional gastrointestinal conditions.

Robigo specializes in biopesticide development by engineering the plant microbiome to enhance crop health and mitigate diseases. The company focuses on creating precision microbial treatments that not only improve plant vitality but also help recover lost agricultural yields. Utilizing advanced microbial engineering and data science, Robigo's products are designed to be effective while ensuring safety for beneficial microbes, pollinators, humans, and the broader environment. This approach enables farmers to boost their productivity and profitability while promoting sustainable farming practices.

Developer of biocomputing technology. The company develops synthetic biology platform to improve the efficiency of biotech R&D, making biological product development as simple and efficient as software development.

Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Fount Bio is a life science company that applies proprietary advances in glycopolymer research for skin health. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts, United States.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.

Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.

ZielBio, Inc. is a biotechnology company focused on identifying high-value disease targets and developing therapeutic interventions to enhance patient outcomes. The company is based in Charlottesville, Virginia, and utilizes its proprietary drug discovery platform, Zielfind, which integrates functional high-throughput screening with large content data analytics to pinpoint valuable targets. ZielBio's lead compound, ZB131, is a humanized monoclonal antibody designed to target cell surface plectin, a significant player in various cancers including ovarian, pancreatic, lung, and colorectal cancer. Founded in 2010, ZielBio aims to transform disease treatment through innovative therapeutic approaches.

Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.

Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing novel small molecule therapeutics for unmet medical needs in autoimmunity and cancer. The company’s lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for multiple autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials for systemic lupus erythematosus. In addition to KZR-616, Kezar is advancing preclinical products, including KZR-TBD, aimed at treating oncology and autoimmune disorders. Founded in 2015, Kezar Life Sciences leverages insights into protein homeostasis, particularly the interplay between protein degradation and secretion, to drive its drug discovery efforts.

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

Oxyrane UK Limited, a biopharmaceutical company, develops novel and biosuperior enzyme replacement therapies for the treatment of lysosomal storage diseases. It provides human lysosomal enzymes that enable clinically effective enzyme uptake and localization using its glycoengineered yeast platform. The company was founded in 2006 and is based in Manchester, United Kingdom. It has locations in Gent, Belgium; and Burlington, Massachusetts.

Cylene Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of small molecule drugs that specifically target the nucleolus to combat cancer. The company specializes in nucleolus targeting agents, which are designed for treating carcinoid/neuroendocrine tumors and pediatric brain tumors, as well as serine/threonine protein kinase inhibitors. Cylene is committed to developing first-in-class targeted agents that activate p53 through a non-genotoxic pathway, thus enhancing treatment outcomes for various cancer types. Additionally, the company offers pre-clinical stage oral drug candidates. Founded in 1997 and based in San Diego, California, Cylene Pharmaceuticals continues to advance its innovative approaches in cancer therapy.

OriGene Technologies, Inc. specializes in the development, manufacturing, and sale of genome-wide research and diagnostic products tailored for academic, pharmaceutical, and biotechnology applications. Founded with a focus on creating a comprehensive collection of full-length human cDNAs, the company offers a diverse range of products, including cDNA clones, shRNA and siRNA tools, and CRISPR/Cas9 genome editing products. Additionally, OriGene provides proteins and lysates, an extensive array of antibodies for immunohistochemistry, and various assay kits, including ELISA and luminex kits. The company supports critical biological research by supplying essential resources for cancer biomarker studies, stem cell research, and other areas. With a commitment to facilitating gene-based research, OriGene distributes its products globally through distributors and online channels. Established in 1995 and based in Rockville, Maryland, OriGene continues to enhance its offerings to meet the evolving needs of researchers in the life sciences field.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

HD Biosciences Inc. is a Shanghai-based biotechnology company that specializes in contract research for drug discovery. The company has developed a comprehensive range of technology platforms and expertise in areas such as assay development, high throughput drug screening, structure-activity relationship (SAR) studies, and hit-to-lead biology solutions. Additionally, it focuses on natural product-based lead discovery. HD Biosciences has established long-term research agreements with notable clients, including Pfizer and Organon, positioning itself as a leader in biology-based drug discovery in China. Its services encompass a variety of stages in the drug discovery process, from assay development and validation to hit identification and in vivo pharmacology, catering to the needs of pharmaceutical and biotech companies globally.